Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy

Acta Radiologica

Volumn 50, Issue 8, 2009, Pages 837-844

  Shankar, S ^a   Dundamadappa, S K ^a   Karam, A R ^a   Stay, R M ^b   Van Sonnenberg, E ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Abdomen GI; Metastases; Neoplasms; Primary; Staging

Indexed keywords

ABDOMEN/GI; METASTASES; NEOPLASMS; PRIMARY; STAGING;

COMPUTERIZED TOMOGRAPHY; MAGNETIC RESONANCE IMAGING; ONCOLOGY; PATHOLOGY; TOMOGRAPHY;

TUMORS;

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; REVIEW; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DISEASE PROGRESSION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PREDICTIVE VALUE OF TESTS; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70350025423     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850903059423     Document Type: Review

References (28)

1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;/152:/1259-69.
2. Mazur MT, Clark HB. Gastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol 1983;/7:/507-19.
3. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology 2003;/65:/187-97.
4. Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including GIST. J Am Coll Surg 2006;/202:/623-9.
5. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003;/90:/1178-86.
6. Wasserberg N, Nunoo-Mensah JW, Beart RW Jr, Ker TS. Is there a role for neoadjuvant treatment with Gleevec for large rectal gastrointestinal stromal tumors? Int J Colorectal Dis 2007;/22:/981-2.
7. Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001;/8:/290-9.
8. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000;/231:/51-8.
9. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;/69:/1334-41.
10. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;/100:/162-8.
11. Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005;/235:/892-8.
12. George S, Desai J. Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors. Curr Treat Options Oncol 2002;/3:/489-96.
13. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Ef.cacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;/347:/ 472-480
14. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and ef.cacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;/358:/ 1421-1423
15. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;/364:/1127-34.
16. Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003;134:656-65; discussion 665-666
17. Reith GD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000;/13:/577-85.
18. King DM. The radiology of gastrointestinal stromal tumors (GIST). Cancer Imaging 2006;/5:/150-6.
19. Sandrasegaran K, Rajesh A, Rushing DA, Rydberg J, Akisik FM, Henley JD. Gastrointestinal stromal tumors: CT and MRI .ndings. Eur Radiol 2005;/15:/1407- 14.
20. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006;/26:/481-95.
21. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;/ 32:/153-62.
22. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;/92:/205-16.
23. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Am J Roentgenol 2002;/179:/1059-62.
24. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;/3:/ 655-664
25. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;/13:/4-7.
26. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST at least in GIST. J Clin Oncol 2007;/25:/1760-4.
27. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;/24:/325-31.
28. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;/45:/ 17-21.